[HTML][HTML] A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
JM Ortiz-Salvador, M Saneleuterio-Temporal… - Journal of the American …, 2019 - Elsevier
Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
JM Ortiz-Salvador… - Journal of the …, 2019 - europepmc.org
Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
JM Ortiz-Salvador… - Journal of the …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
[引用][C] A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
JM Ortiz-Salvador, M Saneleuterio-Temporal… - Journal of the American …, 2019 - cir.nii.ac.jp
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life
setting in 158 patients | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
setting in 158 patients | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
JM Ortiz-Salvador, M Saneleuterio-Temporal… - Journal of the American …, 2019 - jaad.org
Background Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective To …
[PDF][PDF] A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients
JM Ortiz-Salvador, M Saneleuterio-Temporal… - 2019 - academia.edu
Background: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective: To …
demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective: To …